Navigation Links
PSA Can Predicts The Treatment Response In Advanced Prostate Cancer

A new study that has been conducted by researchers from the University of Michigan (U-M) medical school states that patients with lower PSA levels, //7 months after therapy lived longer.

According to a new multicentre study that has been conducted by the Southwest Oncology Group and led by researchers at the U-M Comprehensive Cancer Centre, that has been published in the August 20th issue of the Journal of Clinical Oncology, has explained that a test that is usually done to detect prostate cancer could also help doctors to know when the treatment is working. They further mentioned that the level of the prostate specific antigen, or PSA, in man after seven months of hormone therapy for advanced prostate cancer might foretell how long he would survive.

The study evaluated 1,345 men with prostate cancer that had spread to distant parts of the body. The men were treated with seven months of androgen deprivation therapy, a treatment designed to block the effects of hormones on the cancer. PSA levels were monitored throughout the treatment. The researchers found that men whose PSA dropped below 4.0 ng/ml had a quarter the risk of dying compared to those whose PSA was more than 4.0.

“Our analysis showed that a low or undetectable PSA after seven months of androgen deprivation therapy is a powerful predictor of risk of death in patients with new metastatic prostate cancer. This could allow oncologists to identify patients who are unlikely to do well with this treatment long before they develop clinical signs of treatment resistance,” says lead study author Maha Hussain, M.D., professor of internal medicine at the U-M Medical School.

The researchers found 69 percent of the men maintained a PSA level of less than 4.0 ng/ml after seven months of treatment and 43 percent had an undetectable level of PSA at that time. Patients whose PSA was higher than 4.0 at the end of seven months survived 13 months, while patients whose PSA drop ped below 4.0 but above 0.2 lived 44 months and those whose PSA was undetectable, below 0.2 ng/ml, lived 75 months.

The men in the study were enrolled in a Phase III SWOG trial in which they would receive additional treatment after the seven months of initial hormone therapy. That study seeks to accrue 1,512 men. The patient's PSA level before beginning treatment must be at least 5.0 ng/ml to qualify for the study.

A PSA test measures the level in the blood of prostate specific antigen, an enzyme produced by the prostate gland. It is generally used as an initial screening test to detect prostate cancer.

“What is attractive about using PSA to predict survival in metastatic prostate cancer is that it is an easily measurable factor. These findings could help patients avoid ineffective treatment and could help researchers design further trials,” Hussain says.

Source: EurekAlrt.
'"/>




Related medicine news :

1. Restricted Activity Predicts Disability
2. Fitness Level Predicts Stroke
3. Being Teased Predicts Poor Psychological Functioning in Youth With Cleft Lip
4. Model Predicts Colon Cancer Inheritable Genetic Defects
5. Formula Predicts Osteoporotic Fracture Risk
6. Computer Tool Predicts Effectiveness Of Microbicides
7. New Genetic Test Predicts Eye-Cancer Patients Futures
8. Technology Predicts Outcome of Child Heart Surgery
9. A Secret Dossier Predicts Major Changes At NHS, England
10. Activation of a Particular Brain Region Predicts Altruism: Study
11. New Test Predicts CLL’s Sensitivity to Experimental Drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology: